American Pharmaceutical Partners, Inc.
APP is headquartered in Los Angeles, California, and it has a business office near Chicago, in Schaumburg, Illinois. Its manufacturing and research-and-development facilities are in Melrose Park, Illinois and Grand Island, New York, respectively. Additionally, APP has an efficient distribution center in Bensenville, Illinois and has a Canadian sales-office near Toronto.
APP has distinguished itself by developing injectable pharmaceuticals with added value for its customers. For example, when customers wanted alternate sizes of aqueous Acyclovir Sodium, APP alone offered it in 10 and 20 mL (50mg/mL) units. Customers needing a cost-effective alternative to brand name Vancomycin welcomed APP's 10-gm/unit, pharmacy bulk-pack of sterile Vancomycin Hydrochloride, USP. For those seeking an economical, injectable Haloperidol-alternative, APP developed a complete line of Haloperidol Decanoate Injection(s). Responding to the demand for a cost-efficient alternative to branded Cefazolin for injection, APP introduced its 20-gm/unit, pharmacy bulk-pack Cefazolin. When customers sought a formulation of Vinblastine sulfate that didn't require reconstitution, APP developed the only solution-form of Vinblastine sulfate for injection. Customers looking for more pharmaceuticals that fit their needs better can look to APP for satisfaction.
In the area of discovery, American BioScience, Inc., APP's parent company positions APP for the development of leading-edge therapies. These developments respond to today's needs in oncology and look forward to the next generation of biopharmaceutical compounds that might address unique medical needs yet unmet.
Through its unique association with China American Pharmaceutical Partners (CAPP), APP accesses difficult-to-manufacture and rare raw-materials. These scarce materials compose the therapeutic agents in the present market and anticipate the future for multisource products.
APP has it own dedicated facilities for the development of cost-effective therapies and several developmental partners for supplementing its efforts.
APP distinguishes itself by developing injectable pharmaceutical products with added value for its customers. For example, we offered the first aqueous Acyclovir Sodium injection in 10 and 20 mL (50mg/mL) sizes. We provide a 10-gm., pharmacy bulk-pack of sterile Vancomycin Hydrochloride, USP, a cost-effective alternative to brand name Vancomycin. We developed a complete line of Haloperidol Decanoate Injection(s) as an economical, injectable Haloperidol alternative. We responded to the demand for a cost-efficient alternative to branded Cefazolin for injection with a 20 gram, pharmacy bulk pack Cefazolin. When customers sought a formulation of Vinblastine sulfate that didn't require reconstitution, we developed the only solution-form of Vinblastine sulfate for injection.